Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Martin Ries"'
Autor:
Florian Rosar, Kalle Ribbat, Martin Ries, Johannes Linxweiler, Mark Bartholomä, Stephan Maus, Mathias Schreckenberger, Samer Ezziddin, Fadi Khreish
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-10 (2020)
Abstract Background PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patie
Externí odkaz:
https://doaj.org/article/93fc3c2b704f43bcbaa407c378b121b4
Autor:
Bouamara, Zakaria1 ZakariaBouamara@bayes.city.ac.uk, Jörg-Martin, Ries1 Jörg.Ries@bayes.city.ac.uk
Publikováno v:
Afak of Science Journal / Āfāq li-l-ՙulūm. 2023, Vol. 8 Issue 3, p14-39. 26p.
Autor:
Martin Ries, Fadi Khreish, Mark Bartholomä, Florian Rosar, Samer Ezziddin, Amir Sabet, Niklas Kochems, Matthias Saar, Stephan Maus
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:103-112
Little is known about the efficacy of prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT) against liver metastases of metastatic castration-resistant prostate cancer (mCRPC). We retrospectively analyzed efficacy-related out
Autor:
Samer Ezziddin, Martin Ries, Mathias Schreckenberger, Johannes Linxweiler, Kalle Ribbat, Stephan Maus, Fadi Khreish, Mark Bartholomä, Florian Rosar
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-10 (2020)
Background PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients devel
Autor:
Fadi Khreish, Andrea Schaefer, Samer Ezziddin, Stephan Maus, Sebastian Dewes, Carsten Ohlmann, Martin Ries, Hendrik Bohnenberger, Mark Bartholomä, Florian Rosar, Johannes Linxweiler
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 47:687-694
There is preliminary evidence for prostate-specific membrane antigen (PSMA) upregulation effects of androgen receptor blockade in prostate cancer. In an attempt to find the best condition for PSMA radioligand therapy in metastatic castration-resistan
Autor:
Matthias Saar, Tobias Stemler, Fadi Khreish, Mark Bartholomä, Florian Rosar, Samer Ezziddin, Niklas Ebert, Hendrik Bohnenberger, Stephan Maus, Martin Ries
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 47:721-728
Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-target
Autor:
Amir Sabet, Martin Ries, Christian Rudlowski, Birgit Simon, Carsten Meyer, Fadi Khreish, Samer Ezziddin, Yamen Al-Khalaf
Publikováno v:
Nuklearmedizin. 58:242-248
Aim To evaluate the feasibility of early metabolic response assessment with 18F-FDG PET/CT in patients with breast cancer liver metastases 4 weeks after radioembolization with Yttrium-90 labeled microspheres. Methods 25 patients (mean age 58y, range
Autor:
Florian, Rosar, Peter, Pauly, Martin, Ries, Andrea, Schaefer-Schuler, Stephan, Maus, Mathias, Schreckenberger, Fadi, Khreish, Samer, Ezziddin
Publikováno v:
Am J Nucl Med Mol Imaging
MAG3 scintigraphy with determination of split renal function (SRF) is a standard procedure in patients with metastasized castration-resistant prostate carcinoma (mCRPC) undergoing PSMA radioligand therapy (PSMA-RLT). These patients also receive frequ
Autor:
Tobias Stemler, Florian Rosar, Fadi Khreish, Stephan Maus, MJ Hügle, M Bartholomä, Martin Ries, S Ezziddin
Publikováno v:
58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.
Autor:
Matthias Saar, Niklas Ebert, Fadi Khreish, Samer Ezziddin, Stephan Maus, Tobias Stemler, Mark Bartholomä, Martin Ries, Florian Rosar, Hendrik Bohnenberger
Publikováno v:
58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.
Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-target